(Adnkronos) – TAIPEI, May 3, 2023 /PRNewswire/ — EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A
>>> vai all'articolo completo(Adnkronos) – TAIPEI, May 3, 2023 /PRNewswire/ — EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A
>>> vai all'articolo completo(Adnkronos) – BEIJING, March 4, 2023 /PRNewswire/ — In one proposal by members of the 13th National Committee of the Chinese People’s Political Consultative Conference (CPPCC), the country’s top political advisory body, efforts had been urged to consolidate poverty eradication
Leggi tutto(Adnkronos) – New body to include industry experts: Thomas Zeeb, René Karsenti, Yanming Xiao TEL AVIV, Israel, April 13, 2023 /PRNewswire/ — Fintica AI
Leggi tutto